dr. reddy's labs glp-1 receptor agonists weight management diabetes treatments With the launch of Obeda®, India's first DCGI-approved semaglutide injection for Type 2 Diabetes, we are excited to support care in India with high-quality, accessible and affordable treatment. In a head-to-head dr. reddy's labs glp-1 receptor

Background Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM)

This review synthesizes current evidence on pharmacokinetics, ...

Discover how low dose GLP-1 medications may reduce inflammation through novel mechanisms

Supports overall daily wellness

Key Findings: - Increased risk of going over recommended weight gain limits - Higher chances of preterm birth (from 13% to 17%) - Rising cases of gestational diabetes (15% to 20%) - Nearly half faced high blood pressure issues While baby sizes and C-section rates remained similar, the impact on maternal health is significant

If you are taking medications or have a medical condition, speak with your provider before use